Future Research Perspectives Specific immunotherapy should aim at maximizing allergen-specific IgG responses. IgG subclass responses after AIT are not fully understood to date and require ongoing clinical research, further development of platforms e.g. Immunocap® for IgG1 could provide high throughput value. Further study on the characterization of FcγRIIb on human mast cells may further establish evidence of the translational potential of vaccines containing a single B-cell epitope, which may be able to block some of the specific IgG and block mast cell activation additionally by engaging FcgRIIb. Developing adjuvants that promote B cell responses represents a major challenge in vaccinology today and is relevant for the development of next generation allergy immunotherapies.